Home › Compare › PHGUF vs EQR

PHGUF vs EQR: Dividend Comparison 2026

PHGUF yields 132.45% · EQR yields 5.87%● Live data

vsPost on X →
After 10 years · $10,000 invested · DRIP enabled
🏆 PHGUF wins by $13.48M in total portfolio value
10 years
PHGUF
PHGUF
● Live price
132.45%
Share price
$1.51
Annual div
$2.00
5Y div CAGR
0%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$13.53M
Annual income
$5,443,687.21
Full PHGUF calculator →
EQR
EQR
● Live price
5.87%
Share price
$59.15
Annual div
$3.47
5Y div CAGR
15.8%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$47.8K
Annual income
$5,475.61
Full EQR calculator →

Portfolio growth — PHGUF vs EQR

📍 PHGUF pulled ahead of the other in Year 1

Annual dividend income

🛡️

Recession Test — Did They Cut Dividends?

How each stock treated shareholders during the 3 biggest crises of the last 20 years

Crisis PeriodPHGUFEQR
2008–2009
GFC
— No data— No data
2020 Q1–Q2
COVID
— No data— No data
2022 Q4
Rate Hike
— No data— No data
Based on dividend payment history. "Increased" = dividend grew during crisis. "Maintained" = held within 3%. "Cut" = reduced by more than 3%.
📅

Dividend Calendar Overlap

Combined, PHGUF + EQR cover 0 of 12 months — good coverage

Jan
—
Feb
—
Mar
—
Apr
—
May
—
Jun
—
Jul
—
Aug
—
Sep
—
Oct
—
Nov
—
Dec
—
PHGUF pays
EQR pays
Both pay
Neither
💰

Tax Bracket Optimizer

Which stock is actually better after tax? Adjust your rate to find out.

PHGUF
Annual income on $10K today (after 15% tax)
$11,258.28/yr
After 10yr DRIP, annual income (after tax)
$4,627,134.13/yr
EQR
Annual income on $10K today (after 15% tax)
$499.01/yr
After 10yr DRIP, annual income (after tax)
$4,654.27/yr
At 15% tax rate, PHGUF beats the other by $4,622,479.86/year in after-tax income after 10 years on $10,000
⚖️

Lazy Portfolio Split Optimizer

What's the optimal mix of PHGUF + EQR for your $10,000?

PHGUF: 50%EQR: 50%
100% EQR50/50100% PHGUF
Portfolio after 10yr
$6.79M
Annual income
$2,724,581.41/yr
Blended yield
40.14%
📊

Analyst Conviction Gap

Where Wall Street is most bullish on EQR right now

PHGUF
Analyst Ratings
1
Buy
Consensus: Buy
Altman Z
51.7
Piotroski
6/9
EQR
Analyst Ratings
16
Buy
28
Hold
2
Sell
Consensus: Hold
Price Target
$70.35
+18.9% upside vs current
Range: $63.00 — $78.50
Altman Z
1.8
Piotroski
7/9
Analyst ratings via FMP. Altman Z-Score: >3.0 safe, 1.81–3.0 grey zone, <1.81 distress. Piotroski: 7–9 strong, 0–3 weak.
🏛️

Copy Congress — What Are Politicians Buying?

Senate & House STOCK Act disclosures (last 90 days)

PHGUF buys
0
EQR buys
0
No recent congressional trades found for PHGUF or EQR in the last 90 days.
STOCK Act mandates disclosure within 45 days of transaction. Data via FMP.Full tracker →
MetricPHGUFEQR
Forward yield132.45% ✓5.87%
Annual dividend / share$2.00$3.47 ✓
Payout ratio50%50%
1-year div growth0%0%
5-year div CAGR0%15.8% ✓
Portfolio after 10y$13.53M$47.8K ✓
Annual income after 10y$5,443,687.21 ✓$5,475.61
Total dividends collected$12.40M$23.0K ✓
Payment frequencyquarterlyquarterly
SectorStockREIT
Analyst consensusBuyHold

Year-by-year: PHGUF vs EQR ($10,000, DRIP)

YearPHGUF PortfolioPHGUF Income/yrEQR PortfolioEQR Income/yrGap
1← crossover$23,945$13,245.03$11,380$679.82+$12.6K → PHGUF
2$55,262$29,640.44$13,014$837.25+$42.2K → PHGUF
3$123,061$63,930.66$14,961$1,036.20+$108.1K → PHGUF
4$264,727$133,051.80$17,297$1,289.22+$247.4K → PHGUF
5$550,752$267,494.95$20,121$1,613.15+$530.6K → PHGUF
6$1,109,410$520,104.50$23,561$2,030.84+$1.09M → PHGUF
7$2,166,203$979,134.42$27,783$2,573.54+$2.14M → PHGUF
8$4,104,595$1,786,757.87$33,013$3,284.39+$4.07M → PHGUF
9$7,556,038$3,164,121.24$39,547$4,223.51+$7.52M → PHGUF
10$13,528,648$5,443,687.21$47,791$5,475.61+$13.48M → PHGUF

PHGUF vs EQR: Complete Analysis 2026

PHGUF — Stock

Pharming Group N.V., a biopharmaceutical company, develops and commercialize protein replacement therapies and precision medicines for the treatment of rare diseases and unmet medical needs in the United States, Europe, and internationally. The company's lead product is Ruconest, a recombinant human C1 esterase inhibitor that is used for the treatment of acute hereditary angioedema. It also engages in the development of rhC1INH for the treatment of pre-eclampsia, acute kidney injury, and COVID-19; leniolisib, a phosphoinositide 3-kinase delta (PI3K delta) to treat patients with activated PI3K delta syndrome; and alpha-glucosidase therapy for the treatment of pompe and fabry diseases. The company has a development collaboration and license agreement with Novartis; and a strategic collaboration agreement with Orchard Therapeutics plc for research, development, manufacturing, and commercialization of OTL-105, an investigational ex-vivo autologous hematopoietic stem cell gene therapy for the treatment of hereditary angioedema. Pharming Group N.V. is headquartered in Leiden, the Netherlands.

Full PHGUF Calculator →

EQR — REIT

Equity Residential is committed to creating communities where people thrive. The Company, a member of the S&P 500, is focused on the acquisition, development and management of residential properties located in and around dynamic cities that attract high quality long-term renters. Equity Residential owns or has investments in 305 properties consisting of 78,568 apartment units, located in Boston, New York, Washington, D.C., Seattle, San Francisco, Southern California and Denver.

Full EQR Calculator →
📬

Get this PHGUF vs EQR comparison by email

Save your analysis + weekly dividend insights. Free forever.

More comparisons

PHGUF vs SCHDPHGUF vs JEPIPHGUF vs OPHGUF vs KOPHGUF vs MAIN

⚠️ Educational purposes only. Not financial advice. Congressional trades sourced from SEC STOCK Act filings via FMP. Past performance does not guarantee future results.